<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01135875</url>
  </required_header>
  <id_info>
    <org_study_id>CTC-01</org_study_id>
    <nct_id>NCT01135875</nct_id>
  </id_info>
  <brief_title>Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients</brief_title>
  <official_title>Human Glioblastoma Multiforme (GBM) Circulating Tumor Cells (CTCs) as Early, Less Invasive Markers of Progression and Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if tumor cells can be detected in the blood of
      patients diagnosed with a brain tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite aggressive therapies, Glioblastoma Multiforme (GBM) is rapidly fatal. GBMs are
      increasingly recognized for occasionally metastasizing through the peripheral blood to
      distant locations. This research study involves the detection and novel characterization of
      human GBM (hGBM) circulating tumor cells (CTCs) within the peripheral blood of brain tumor
      patients by identifying their unique cell surface antigen profile, determining an optimal
      isolation protocol, and quantitatively and qualitatively reporting the yield and
      characteristics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of Human GBM CD Antigen Signature.</measure>
    <time_frame>3 Years</time_frame>
    <description>Already established and stored GBM cell lines will be screened for CD antigens to confirm that a selective cell surface antigen can be identified.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification &amp; Isolation of Human GBM Cells in Seeded Normal Control Human Blood.</measure>
    <time_frame>3 Years</time_frame>
    <description>Frozen and fresh human blood will be seeded with human GBM cells from established stored GBM cell lines and subjected to antibody-based cell identification and isolation procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective Isolation of GBM Tumor Cells in GBM Patient Blood.</measure>
    <time_frame>3 Years</time_frame>
    <description>Circulating tumor cells will be isolated from blood drawn from GBM patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prospective Evaluation of the Routine Medical History of GBM Patients.</measure>
    <time_frame>3 Years</time_frame>
    <description>Medical records of GBM patients will be used to determine how circulating tumor cells impact outcome.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">130</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>GBM Patients</arm_group_label>
    <description>GBM Patients with a histologically confirmed or suspected diagnosis of glioblastoma multiforme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Controls</arm_group_label>
    <description>Normal Controls will be adult volunteers who identify themselves as not having been diagnosed with a glioblastoma multiforme.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GBM Patients</intervention_name>
    <description>2 teaspoons of blood will be collected during select clinic visits.</description>
    <arm_group_label>GBM Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Controls</intervention_name>
    <description>2 teaspoons of blood will be collected once.</description>
    <arm_group_label>Normal Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited during routine interactions with the investigators.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 89 years of age

          -  Weight of at least 110 pounds

          -  Able to provide informed consent for self

        Exclusion Criteria:

          -  Patients with active malignant tumors other than GBM
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brent Reynolds, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2010</study_first_submitted>
  <study_first_submitted_qc>June 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <last_update_submitted>October 15, 2013</last_update_submitted>
  <last_update_submitted_qc>October 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GBM</keyword>
  <keyword>Brain Tumor</keyword>
  <keyword>Brain Neoplasm</keyword>
  <keyword>Control</keyword>
  <keyword>Normal Control</keyword>
  <keyword>Volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

